ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

In the News

What Is Neoadjuvant Chemotherapy?

If you or a loved one has been diagnosed with cancer, your care team may recommend chemotherapy, one of the most common types of cancer treatment available. Chemotherapy involves the use of medications that Read More

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrintโ€™s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients [โ€ฆ]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go โ€œbeyond the mammogramโ€ in a portrait series illustrating people touched by breast cancer.

News

Media Releases

Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024

December 12th, 2024|

Gene expression analysis reveals MammaPrintยฎ as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More

Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024

December 11th, 2024|

New data reinforces findings from MINDACT supporting MammaPrintยฎ in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancerย  IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ€“ December 11, 2024 โ€“ Read More